Recurrent major depressive disorder: Imbalance of neurokinin (NK)-1 and NK-2 receptor expression in monocytes

Pharmacological Research

Volumn 68, Issue 1, 2013, Pages 24-30

  Bardelli, Claudio ^a   Amoruso, Angela ^a   Manzetti, Elena ^b   Fresu, Luigia Grazia ^a   Valsesia, Roberta ^c   Zeppegno, Patrizia ^a   Brunelleschi, Sandra ^a,d  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b ASL VC   (Italy)

^c Department of Mental Health   (Italy)

^d Azienda Ospedaliero Universitaria Maggiore della Carità   (Italy)

Author keywords

Monocytes; Neurokinin A; NF B; NK 1 and NK 2 receptors; Recurrent major depressive disorder; Substance P

Indexed keywords

ANTIDEPRESSANT AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEUROKININ 1 RECEPTOR; NEUROKININ 2 RECEPTOR; NEUROKININ A; SUBSTANCE P; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL ASSAY; CELL ISOLATION; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; MAJOR DEPRESSION; MALE; MOLECULAR PATHOLOGY; MONOCYTE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; RECURRENT DISEASE; WESTERN BLOTTING;

DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; MONOCYTES; NEUROKININ A; NEUROTRANSMITTER AGENTS; NF-KAPPA B; RECEPTORS, NEUROKININ-1; RECEPTORS, NEUROKININ-2; SUBSTANCE P; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84872326236     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2012.10.022     Document Type: Article

References (46)

1. R. Patacchini, A. Lecci, P. Holzer, and C.A. Maggi Newly discovered tachykinins raise new questions about their peripheral role and the tachykinin nomenclature Trends in Pharmacological Sciences 25 2004 1 3
2. A.M. Khawala, and D.F. Rogers Tachykinins: receptor to effector International Journal of Biochemistry and Cell Biology 28 1996 721 738
3. J.E. Linley, L. Ooi, L. Pettinger, H. Kirton, J.P. Boyle, and C. Peers Reactive oxygen species are second messengers of neurokinin signaling in peripheral sensory neurons Proceedings of the National Academy of Sciences of the United States of America 109 2012 E1578 E1586
4. K. Ebner, P. Muigg, G. Singewald, and N. Singewald Substance P in stress and anxiety. NK-1 receptor antagonism interacts with key brain areas of the stress circuitry Annals of the New York Academy of Sciences 1144 2008 61 73
5. M. Nagano, F. Saitow, E. Haneda, S. Konishi, M. Hayashi, and H. Suzuki Distribution and pharmacological characterization of primate NK-1 and NK-3 tachykinin receptors in the central nervous system of the rhesus monkey British Journal of Pharmacology 147 2006 316 323
6. G. Griebel, and F. Holsboer Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning Nature Reviews. Drug Discovery 11 2012 462 478
7. M. Nagano, T. Oishi, and H. Suzuki Distribution and pharmacological characterization of primate NK-2 tachykinin receptor in the central nervous system of the rhesus monkey Neuroscience Letters 503 2011 23 26
8. A. Holmes, M. Heilig, N.M.J. Rupniak, T. Steckler, and G. Griebel Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders Trends in Pharmacological Sciences 24 2003 580 588
9. C. De Felipe, J.F. Herrero, J.A. O'Brien, J.A. Palmer, C.A. Doyle, and A.J.H. Smith Altered nociception, analgesia and aggression in mice lacking the receptor for substance P Nature 392 1998 394 397
10. M.S. Kramer, N. Cutler, J. Feighner, R. Shrivastava, J. Carman, and J.J. Sramek Distinct mechanisms for antidepressant activity by blockade of central substance P receptors Science 281 1998 1640 1645
11. L. Santarelli, G. Gobbi, P.C. Debs, E.L. Sibille, P. Blier, and R. Hen Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotoninergic functions Proceedings of the National Academy of Sciences of the United States of America 98 2001 1912 1917
12. M. Keller, S. Montgomery, W. Ball, M. Morrison, D. Snavely, and G. Liu Lack of efficacy of the substance P (neurokinin 1 receptor) antagonist aprepitant in the treatment of major depressive disorder Biological Psychiatry 59 2006 216 223
13. Y.K. Kim, K.S. Na, K.H. Shin, H.Y. Jung, S.H. Choi, and J.B. Kim Cytokine imbalance in the pathophysiology of major depressive disorder Progress in Neuro-Psychopharmacology and Biological Psychiatry 31 2007 1044 1053
14. A.H. Miller, V. Maletic, and C.L. Raison Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression Biological Psychiatry 65 2009 732 741
15. T.W.W. Pace, T.C. Mletzko, O. Alagbe, D.L. Musselman, C.B. Nemeroff, and A.H. Miller Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress American Journal of Psychiatry 163 2006 1630 1633
16. A. Seidel, V. Arolt, M. Hunstiger, L. Rink, A. Behnisch, and H. Kirchner Major depressive disorder is associated with elevated monocyte counts Acta Psychiatrica Scandinavica 94 1996 198 204
17. M. Maes, R. Smith, and S. Scharpe The monocyte/T-lymphocyte hypothesis of major depression Psychoneuroendocrinology 20 1995 111 116
18. A. Amoruso, C. Bardelli, G. Gunella, F. Ribichini, and S. Brunelleschi A novel activity for substance P: stimulation of peroxisome proliferator-activated receptor-γ protein expression in human monocytes and macrophages British Journal of Pharmacology 154 2008 144 152
19. 1 receptors in human alveolar macrophages: superoxide anion production, cytokine release and involvement of NF-κB pathway British Journal of Pharmacology 145 2005 385 396
20. 1 receptors British Journal of Pharmacology 100 1990 417 420
21. W.Z. Ho, J.P. Lai, X.H. Zhu, M. Uvaydova, and S.D. Douglas Human monocytes and macrophages express substance P and neurokinin-1 receptor Journal of Immunology 159 1997 5654 5660
22. J.P. Lai, W.Z. Ho, L.E. Kilkpatrick, X. Wang, F. Tuluc, and H.M. Korchak Full-length and truncated neurokinin-1 receptor expression and function during monocyte/macrophage differentiation Proceedings of the National Academy of Sciences of the United States of America 103 2006 7771 7776
23. I. Marriott, M.J. Mason, A. Elhofy, and Bost K.L. Substance P activates NF-κB without elevations in intracellular calcium in murine macrophages and dendritic cells Journal of Neuroimmunology 102 2000 163 171
24. M. Lotz, J.H. Vaugham, and D.A. Carson Effects of neuropeptides on production of inflammatory cytokines by human monocytes Science 241 1998 1218 1221
25. D. Renzi, B. Pellegrini, F. Tonelli, C. Surrenti, and A. Calabrò Substance P (neurokinin-1) and neurokinin A (neurokinin-2) receptor gene and protein expression in the healthy and inflamed human intestine American Journal of Pathology 157 2000 1511 1522
26. P. Cunin, A. Caillon, M. Corvaisier, E. Garo, M. Scotet, and S. Blanchard The tachyikinin substance P and hemokinin-1 favor the generation of IL-β, IL-23, and TNF-like 1A expression by monocytes Journal of Immunology 186 2001 4175 4182
27. W.H. Berrettini, D.R. Rubinow, J.I. Nurnberger Jr., S. Simmons-Alling, R.M. Post, and E.S. Gershon CSF substance P immunoreactivity in affective disorders Biological Psychiatry 20 1985 965 970
28. B. Bondy, T.C. Bagnai, C. Minov, C. Schule, M.J. Schwarz, and P. Zwanzger Substance P levels are increased in major depression: preliminary results Biological Psychiatry 53 2003 538 542
29. P.W.J. Burnet, and P.J. Harrison Substance P (NK1) receptors in the cingulated cortex in unipolar and bipolar mood disorder and schizophrenia Biological Psychiatry 47 2000 80 83
30. L.L. Carpenter, L. Bayat, F. Moreno, M.A. Kling, L.H. Price, and A.R. Tyrka Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy Psychiatry Research 157 2008 123 129
31. G. Cizza, A.H. Marquez, F. Eskandari, I.C. Christie, S. Torvik, and M.N. Silverman Elevated neuroimmune biomarkers in sweat patches and plasma of premenopausal women with major depressive disorders in remission: the POWER study Biological Psychiatry 64 2008 907 911
32. M. Deuschle, P. Sander, I. Herpfer, B.L. Fiebich, I. Heuser, and K. Lieb Substance P in serum and cerebrospinal fluid of depressed patients: no effect of antidepressant treatment Psychiatry Research 136 2005 1 6
33. T.D. Geracioti, L.L. Carpenter, M.J. Owens, D.G. Baker, N.N. Ekhator, and P.S. Horn Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression American Journal of Psychiatry 163 2006 637 643
34. L. Li, X. Gao, J. Zhao, X. Ji, H. Wei, and Y. Luo Plasma and cerebrospinal fluid substance P in post-stroke patients with depression Psychiatry and Clinical Neurosciences 63 2009 298 304
35. K. Lieb, J. Walden, H. Grunze, B.L. Fiebich, M. Berger, and C. Nonnann Serum levels of substance P and response to antidepressant pharmacotherapy Pharmacopsychiatry 37 2004 238 239
36. C.A. Stockmeier, X. Shi, L. Konick, J.C. Overholser, G. Jurjus, and H.Y. Meltzer Neurokinin-1 receptors are decreased in major depressive disorder Neuroreport 13 2002 1223 1227
37. T.M. Fong, S.A. Anderson, H. Yu, R.R. Huang, and C.D. Strader Differential activation of intracellular effectors by two isoforms of neurokinin-1 receptor Molecular Pharmacology 41 1992 24 30
38. F. Tuluc, J.P. Lai, L.E. Kilkpatrick, D.L. Evans, and S.D. Douglas Neurokinin 1 receptor isoforms and the control of innate immunity Trends in Immunology 30 2009 271 276
39. S.D. Douglas, J.P. Lai, F. Tuluc, L. Schwarz, and L.E. Kilkpatrick Neurokinin-1 receptor expression and function in human macrophages and brain. Perspective on the role of HIV neuropathogenesis Annals of the New York Academy of Sciences 1144 2008 90 96
40. I. Chernova, J.P. Lai, H. Li, L. Schwarz, F. Tuluc, and H.M. Korchak Substance P (SP) enhances CCL5-induced chemotaxis and intracellular signalling in human monocytes, which express the truncated neurokinin-1 receptor (NK1R) Journal of Leukocyte Biology 85 2009 154 164
41. 3H-SP receptor binding sites in subjects affected by mood disorders and schizophrenia European Journal of Neuroscience 21 2005 1712 1718
42. 2 receptor variants Biochemical Pharmacology 76 2008 476 481
43. J.W. Koo, S.J. Russo, D. Ferguson, E.J. Nestler, and R.S. Duman Nuclear factor-κB is a critical mediator of stress-impaired neurogenesis and depressive behavior Proceedings of the National Academy of Sciences of the United States of America 107 2010 2669 2674
44. J. Bondeson, K.A. Browne, F.M. Brennan, B.M. Foxwell, and M. Feldmann Seklective regulation of cytokine induction by adenoviral gene transfer of IκBα into human macrophages: lipopolysaccharide-induced, but not zymosan-induced, proinflammatory cytokines are inhibited, but IL-10 is nuclear factor-κB independent Journal of Immunology 162 1999 2939 2945
45. L. Lavagno, G. Gunella, C. Bardelli, S. Spina, L.G. Fresu, and I. Viano Anti-inflammatory drugs and tumor necrosis factor-α production from human monocytes: role of transcription factor NF-κB and implication for rheumatoid arthritis therapy European Journal of Pharmacology 501 2004 199 208
46. S. Lanquillon, J.C. Krieg, U. Bening-Abu-Shach, and H. Vedder Cytokine production and treatment response in major depressive disorder Neuropsychopharmacology 22 2000 370 379